RxDoctor Payments Data

Karlie Cason, PA

Physician Assistant · Chandler, TXNPI 1427294867

Payments from drug & device makers

$4,640in general payments, 2019–2025

Across 191 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$950
  • Sanofi$933
  • AbbVie$680
  • UCB, Inc.$388
  • Sanofi-aventis U.S. LLC$264
  • Arcutis Biotherapeutics, Inc.$238
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$4,11489%
  • Education$52611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,640 in reported general payments places this provider in the 85th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$360,067
Medicare patients
1,238
Services billed
7,268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa33$698,823
Dupixent PenDupilumab165$643,596
OtezlaApremilast17$78,132
XolairOmalizumab12$32,109
Clobetasol Propionate239$8,851
Ketoconazole301$4,374
Triamcinolone Acetonide191$2,773
Doxycycline Hyclate137$2,357
Azelaic Acid12$1,942
Tacrolimus25$1,479
Metronidazole31$1,309
Fluorouracil20$1,305
Colchicine12$926
Levocetirizine Dihydrochloride83$789
Hydrocortisone106$580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$138$78,13217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Chandler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →